Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | TP53 | P04637 | 6/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | THPO | P40225 | 2/20 | 0.54 |
| ▸ | FPR2 | P25090 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | SCN1A | P35498 | 3/20 | 0.52 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.52 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625167 | 0.81 | FABP4 (0.49) | CYP3A4CYP1A2CYP2C19CYP2C9MEN1 | |
| SCHEMBL4128136 | 0.80 | CYP3A4 (0.58) | CYP3A4CYP1A2CYP2C19CYP2C9MEN1 | |
| SCHEMBL11576786 | 0.79 | FABP4 (0.47) | TP53ALDH1A1MAPK1NPSR1FABP4 | |
| SCHEMBL3489059 | 0.79 | CYP3A4 (0.47) | CYP3A4CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL3490267 | 0.79 | CYP3A4 (0.47) | CYP3A4CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL644543 | 0.78 | FABP4 (0.73) | ALDH1A1MAPK1LMNATHRBFABP4 | |
| SCHEMBL11629929 | 0.77 | ALDH1A1 (0.59) | CYP3A4CYP1A2CYP2C19CYP2C9MEN1 | |
| SCHEMBL7134091 | 0.76 | FABP4 (0.64) | CYP3A4CYP1A2CYP2C19CYP2C9MEN1 | |
| Hydrochloric Acid SCHEMBL11625827 | 0.75 | KMT2A (0.58) | CYP3A4CYP1A2CYP2C19CYP2C9MEN1 | |
| SCHEMBL3490280 | 0.75 | NR3C1 (0.42) | CYP3A4CYP1A2CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9192569-B2 | Formulations for infusion of type B lantibiotics | NOVACTA BIOSYSTEMS LIMITED (GB) | 2015-11-24 | — | — | US | disclosed |
| US-9006392-B2 | Actagardine derivatives, and pharmaceutical use thereof | NOVACTA BIOSYSTEMS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-8729031-B2 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2014-05-20 | — | — | US | disclosed |
| EP-2603204-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | Novacta Biosystems Limited (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-05-30 | — | — | US | disclosed |
| US-20120302728-A1 | Actagardine Derivatives, and Pharmaceutical Use Thereof | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| WO-2012020219-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| EP-2393829-A1 | ACTAGARDINE DERIVATIVES | Novacta Biosystems Limited (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294723-A1 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-12-01 | — | — | US | disclosed |
| WO-2011095769-A1 | ACTAGARDINE DERIVATIVES, AND PHARMACEUTICAL USE THEREOF | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-08-11 | — | — | WO | disclosed |
| WO-2010089544-A1 | ACTAGARDINE DERIVATIVES | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | SLC5A2, SLC5A11, SPTSSB | CYP3A4 4601/4885CYP1A2 4692/4885CYP2C19 4178/4885 |
| US-20120302728-A1 | Actagardine Derivatives, and Pharmaceutical Use Thereof | GALR2, GALR1, GALR3 | CYP3A4 2881/4885CYP1A2 3136/4885CYP2C19 1954/4885 |
| US-20110294723-A1 | Compounds | SLC11A2, SDHA, SDHB | CYP3A4 374/4885CYP1A2 165/4885CYP2C19 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.